Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
1994 1
1995 2
1997 1
1999 1
2000 1
2004 2
2008 2
2009 3
2010 3
2011 2
2012 1
2013 2
2014 6
2015 5
2016 2
2017 1
2018 2
2019 3
2020 4
2021 11
2022 12
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

59 results
Results by year
Filters applied: . Clear all
Page 1
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Kersting S, Dubois J, Nasserinejad K, Dobber JA, Mellink C, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken H, Levenga H, Tick LW, Terpstra WE, Tonino SH, Boyer M, Mobasher M, Levin MD, Kater AP; HOVON CLL study group. Kersting S, et al. Among authors: posthuma efm. Lancet Haematol. 2022 Mar;9(3):e190-e199. doi: 10.1016/S2352-3026(22)00034-5. Lancet Haematol. 2022. PMID: 35240075 Clinical Trial.
Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands.
Brink M, Minnema MC, Visser O, Levin MD, Posthuma EFMW, Broijl A, Sonneveld P, van der Klift M, Roeloffzen WWH, Westerman M, van Rooijen CR, Geerts PAF, Zweegman S, van de Donk NWCJ, Dinmohamed AG. Brink M, et al. Among authors: posthuma efmw. Blood Cancer J. 2022 Mar 15;12(3):41. doi: 10.1038/s41408-022-00640-6. Blood Cancer J. 2022. PMID: 35292622 Free PMC article. No abstract available.
[Peripheral intravenous catheter-related phlebitis].
van der Sar-van der Brugge S, Posthuma EF. van der Sar-van der Brugge S, et al. Among authors: posthuma ef. Ned Tijdschr Geneeskd. 2011;155(40):A3548. Ned Tijdschr Geneeskd. 2011. PMID: 21988756 Dutch.
Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era.
Dinnessen MAW, Maas CCHM, Tonino SH, Visser O, Posthuma EFM, Blijlevens NMA, Kersten MJ, Lugtenburg PJ, Dinmohamed AG. Dinnessen MAW, et al. Among authors: posthuma efm. Leukemia. 2022 May;36(5):1416-1420. doi: 10.1038/s41375-022-01535-y. Epub 2022 Mar 4. Leukemia. 2022. PMID: 35246605 No abstract available.
Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2018.
van der Straten L, Maas CCHM, Levin MD, Visser O, Posthuma EFM, Doorduijn JK, Langerak AW, Kater AP, Dinmohamed AG. van der Straten L, et al. Among authors: posthuma efm. Blood Cancer J. 2022 Apr 20;12(4):72. doi: 10.1038/s41408-022-00669-7. Blood Cancer J. 2022. PMID: 35444185 Free PMC article. No abstract available.
59 results